Lineage Cell Therapeutics Inc (LCTX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE MKT

Key Metrics

• Price: $1.96
• Market Cap: $437.62M
• EPS: $-0.29
• 52-Week High: $2.09
• 52-Week Low: $0.36

Market Sentiment

Lineage Cell Therapeutics Inc currently has a Bullish sentiment score of 0.34.

About Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc. is a forward-looking clinical-stage biotechnology firm based in Carlsbad, California, specializing in the development and commercialization of innovative cell-based therapies for degenerative diseases. With a strong emphasis on regenerative medicine, the company harnesses proprietary technologies to address significant unmet medical needs globally. Lineage boasts a robust and diverse pipeline supported by strategic collaborations, positioning it for substantial...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Lineage Cell Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does LCTX pay dividends?

Lineage Cell Therapeutics Inc (LCTX) does not currently pay a regular dividend.

What is LCTX's market cap?

Lineage Cell Therapeutics Inc (LCTX) has a market capitalization of $437.62M with a current stock price of $1.96.